Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Birth ; 46(2): 289-299, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-30251270

RESUMO

BACKGROUND: This study aims to examine hospital variation in both maternal and neonatal morbidities and identify institutional characteristics associated with hospital performance in a combined measure of maternal and neonatal outcomes. METHODS: Using the California Linked Birth File containing data from birth certificate and hospital discharge records, we identified 1 322 713 term births delivered at 248 hospitals during 2010-2012. For each hospital, a risk-standardized rate of severe maternal morbidities and a risk-standardized rate of severe newborn morbidities were calculated after adjusting for patient clinical risk factors. Hospitals were ranked based on combined information on their maternal and newborn morbidity rates. RESULTS: Risk-standardized severe maternal and severe newborn morbidity rates varied substantially across hospitals (10th to 90th percentile range = 67.5-148.2 and 141.8-508.0 per 10 000 term births, respectively), although there was no significant association between the two (P = 0.15). Government hospitals (non-Federal) were more likely than other hospitals to be in worse rank quartiles (P value for trend = 0.004), whereas larger volume was associated with better rank among hospitals in the first three quartiles (P = 0.004). The most prevalent morbidities that differed progressively across hospital rank quartiles were severe hemorrhage, disseminated intravascular coagulation, and heart failure during procedure/surgery for mothers, and severe infection, respiratory complication, and shock/resuscitation for neonates. CONCLUSIONS: Hospitals with low maternal morbidity rates may not have low neonatal morbidity rates and vice versa, highlighting the importance of assessing joint maternal-newborn outcomes in order to fully characterize a hospital's obstetrical performance. Hospitals with smaller volume and government ownership tend to have less desirable outcomes and warrant additional attention in future quality improvement efforts.


Assuntos
Hospitais/normas , Doenças do Recém-Nascido/epidemiologia , Complicações do Trabalho de Parto , Obstetrícia/normas , Indicadores de Qualidade em Assistência à Saúde , Adulto , Declaração de Nascimento , California/epidemiologia , Cesárea/estatística & dados numéricos , Feminino , Idade Gestacional , Hospitais/estatística & dados numéricos , Humanos , Recém-Nascido , Morbidade , Alta do Paciente , Distribuição de Poisson , Gravidez , Análise de Regressão , Fatores de Risco , Adulto Jovem
2.
Am J Obstet Gynecol ; 204(5): 411.e1-411.e11, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21316642

RESUMO

OBJECTIVE: We sought to characterize serum angiogenic factor profile of women with complete placenta previa and determine if invasive trophoblast differentiation characteristic of accreta, increta, or percreta shares features of epithelial-to-mesenchymal transition. STUDY DESIGN: We analyzed gestational age-matched serum samples from 90 pregnant women with either complete placenta previa (n = 45) or uncomplicated pregnancies (n = 45). Vascular endothelial growth factor (VEGF), placental growth factor, and soluble form of fms-like-tyrosine-kinase-1 were immunoassayed. VEGF and phosphotyrosine immunoreactivity was surveyed in histological specimens relative to expression of vimentin and cytokeratin-7. RESULTS: Women with previa and invasive placentation (accreta, n = 5; increta, n = 6; percreta, n = 2) had lower systemic VEGF (invasive previa: median 0.8 [0.02-3.4] vs control 6.5 [2.7-10.5] pg/mL, P = .02). VEGF and phosphotyrosine immunostaining predominated in the invasive extravillous trophoblasts that coexpressed vimentin and cytokeratin-7, an epithelial-to-mesenchymal transition feature and tumorlike cell phenotype. CONCLUSION: Lower systemic free VEGF and a switch of the interstitial extravillous trophoblasts to a metastable cell phenotype characterize placenta previa with excessive myometrial invasion.


Assuntos
Placenta Acreta/metabolismo , Placenta Prévia/metabolismo , Trofoblastos/metabolismo , Fator A de Crescimento do Endotélio Vascular/metabolismo , Adulto , Estudos de Casos e Controles , Transição Epitelial-Mesenquimal , Feminino , Humanos , Queratina-7/metabolismo , Fosfotirosina/metabolismo , Placenta Acreta/patologia , Fator de Crescimento Placentário , Placenta Prévia/patologia , Gravidez , Proteínas da Gravidez/sangue , Trofoblastos/patologia , Receptor 1 de Fatores de Crescimento do Endotélio Vascular/sangue , Vimentina/metabolismo
3.
J Matern Fetal Neonatal Med ; 24(5): 673-9, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-20937006

RESUMO

OBJECTIVE: To evaluate cord blood erythropoietin (EPO) and interleukin-6 (IL-6) levels to predict preterm infants at risk of developing intraventricular hemorrhage (IVH). METHODS: Levels of umbilical cord EPO, acid-base status and IL-6 were analyzed in 116 consecutive, preterm newborns (GA at delivery: 29 [23-34 ] weeks) born to mothers who had a clinically indicated amniocentesis to rule out infection. Early-onset neonatal sepsis (EONS) was diagnosed using symptoms, hematological criteria and blood cultures. RESULTS: IVH was diagnosed by cranial ultrasounds. The prevalence of IVH in our population was 25% (29/116). There was a direct relationship between cord blood EPO and cord blood IL-6 concentration (r = 0.225, p = 0.014), independent of GA at birth. Elevated cord blood EPO levels (r = 0.182, p = 0.016) and GA at birth (r =  -0.236, p = 0.004) remained significant independent factors associated with the risk of IVH, when evaluated with stepwise logistic regression analyses. Cord blood IL-6, pH, and EONS were not associated with IVH. These relationships remained following correction for GA at birth (p = 0.027). CONCLUSIONS: Our results suggest that elevation in cord blood EPO may predict newborns at risk for IVH, independent of fetal inflammatory status. Further studies are warranted to confirm this association.


Assuntos
Eritropoetina/sangue , Doenças do Prematuro/sangue , Interleucina-6/sangue , Hemorragias Intracranianas/sangue , Adulto , Biomarcadores/sangue , Corioamnionite/sangue , Feminino , Sangue Fetal/metabolismo , Humanos , Recém-Nascido , Gravidez , Nascimento Prematuro/sangue , Estudos Prospectivos , Sepse/sangue , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA